2NVS : FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool
The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s NVS Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of patients ...